Eli Gelman - Amdocs CEO

DOX
 Stock
  

USD 84.45  1.14  1.37%   

  CEO
Mr. Eli Gelman serves as Director of the Company effective September 30, 2018. Mr. Gelman was a director of Amdocs since 2002. Mr. Gelman became the President and Chief Executive Officer of Amdocs Management Limited, our whollyowned subsidiary, in 2010. From 2010 until 2013, Mr. Gelman served as a director of Retalix, a global software company, and during 2010, he also served as its Chairman. From 2008 to 2010, Mr. Gelman devoted his time to charitable matters focused on youth education. He served as Executive Vice President of Amdocs Management Limited from 2002 until 2008 and as our Chief Operating Officer from 2006 until 2008. Prior to 2002, he was a Senior Vice President, where he headed our U.S. sales and marketing operations and helped spearhead our entry into the customer care and billing systems market. Before that, Mr. Gelman was an account manager for our major European and North American installations, and has led several major software development projects. Before joining Amdocs, Mr. Gelman was involved in the development of realtime software systems for communications networks and software projects for NASA. Mr. Gelmans qualifications to serve on our Board of Directors include his more than two decades of service to Amdocs and its customers, including as our Chief Operating Officer. With more than 30 years of experience in the software industry, he possesses a vast institutional knowledge and strategic understanding of our organization and industry.
Age: 58  CEO Since 2018      
(44) 1481 728444  www.amdocs.com

Amdocs Management Efficiency

Amdocs Limited has Return on Asset of 5.76 % which means that on every $100 spent on asset, it made $5.76 of profit. This is considered to be average in the sector. In the same way, it shows return on shareholders equity (ROE) of 14.03 %, implying that it generated $14.03 on every 100 dollars invested. Amdocs management efficiency ratios could be used to measure how well the company manages its routine affairs as well as how well it operates its assets and liabilities. Return on Invested Capital is likely to rise to 0.44 in 2022, whereas Return on Investment is likely to drop 12.42 in 2022. Amdocs Tax Assets are fairly stable at the moment as compared to the past year. Amdocs reported Tax Assets of 135.66 Million in 2021. Revenue to Assets is likely to rise to 0.60 in 2022, whereas Total Assets are likely to drop slightly above 7 B in 2022.
The company has 879.12 M in debt with debt to equity (D/E) ratio of 0.25, which may show that the company is not taking advantage of profits from borrowing. Amdocs Limited has a current ratio of 1.47, which is typical for the industry and considered as normal. Debt can assist Amdocs until it has trouble settling it off, either with new capital or with free cash flow. So, Amdocs' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Amdocs Limited sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Amdocs to invest in growth at high rates of return. When we think about Amdocs' use of debt, we should always consider it together with cash and equity.

Similar Executives

Amdocs Limited, through its subsidiaries, provides software and services worldwide. Amdocs Limited was founded in 1988 and is headquartered in Chesterfield, Missouri. Amdocs operates under SoftwareInfrastructure classification in the United States and is traded on NASDAQ Exchange. It employs 29000 people. Amdocs Limited (DOX) is traded on NASDAQ Exchange in USA. It is located in Hirzel House, Smith Street, St. Peter Port, Island of Guernsey GY1 2NG, United Kingdom and employs 29,000 people. Amdocs is listed under Business Services category by Fama And French industry classification.

Amdocs Limited Leadership Team

Elected by the shareholders, the Amdocs' board of directors comprises two types of representatives: Amdocs inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Amdocs. The board's role is to monitor Amdocs' management team and ensure that shareholders' interests are well served. Amdocs' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Amdocs' outside directors are responsible for providing unbiased perspectives on the board's policies.
Richard LeFave, Independent Director
Matthew Smith, Corporate Secretary
John MacDonald, Director
Adrian Gardner, Independent Director
Tamar RapaportDagim, Senior Vice President and CFO of Amdocs Management Limited
Zohar Zisapel, Independent Director
Simon Olswang, Independent Director
Anshoo Gaur, Division President of Amdocs Devel. Center India Pvt Ltd
Elizabeth McDermon, Secretary and VP of Corporate Strategy of Amdocs Inc.
Giora Yaron, Director
Shuky Sheffer, Senior Vice President and President of Customer Business Group, Amdocs Management Limited
John McLennan, Independent Director
Robert Minicucci, Independent Chairman of the Board
Matt Smith, IR Contact Officer
Clayton Christensen, Director
Julian Brodsky, Independent Director
James Kahan, Independent Director
Eli Gelman, Director, Member of Technology and Innovation Committee, CEO of Amdocs Management Limited and President of Amdocs Management Limited
Rajat Raheja, Division President Amdocs Development Center India Pvt. Ltd

Amdocs Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Amdocs a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Amdocs Investors Sentiment

The influence of Amdocs' investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Amdocs. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock markets does not have a solid backing from leading economists and market statisticians.

Amdocs Implied Volatility

    
  33.35  
Amdocs' implied volatility exposes the market's sentiment of Amdocs Limited stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Amdocs' implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Amdocs stock will not fluctuate a lot when Amdocs' options are near their expiration.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Amdocs in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Amdocs' short interest history, or implied volatility extrapolated from Amdocs options trading.

Current Sentiment - DOX

Amdocs Limited Investor Sentiment

Greater number of Macroaxis users are currently bullish on Amdocs Limited. What is your sentiment towards investing in Amdocs Limited? Are you bullish or bearish?
Bullish
Bearish
98% Bullish
2% Bearish

Pair Trading with Amdocs

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Amdocs position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Amdocs will appreciate offsetting losses from the drop in the long position's value.

Amdocs Pair Correlation

Correlation Analysis For Direct Indexing and Tax-loss Harvesting

The ability to find closely correlated positions to Amdocs could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Amdocs when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Amdocs - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Amdocs Limited to buy it.
The correlation of Amdocs is a statistical measure of how it moves in relation to other equities. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Amdocs moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Amdocs Limited moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Amdocs can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
Continue to Investing Opportunities. Note that the Amdocs Limited information on this page should be used as a complementary analysis to other Amdocs' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.

Complementary Tools for Amdocs Stock analysis

When running Amdocs Limited price analysis, check to measure Amdocs' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Amdocs is operating at the current time. Most of Amdocs' value examination focuses on studying past and present price action to predict the probability of Amdocs' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Amdocs' price. Additionally, you may evaluate how the addition of Amdocs to your portfolios can decrease your overall portfolio volatility.
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Go
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Go
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Go
CEO Directory
Screen CEOs from public companies around the world
Go
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Go
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Go
Is Amdocs' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Amdocs. If investors know Amdocs will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Amdocs listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth YOY
0.41
Market Capitalization
10.4 B
Quarterly Revenue Growth YOY
0.092
Return On Assets
0.0601
Return On Equity
0.16
The market value of Amdocs Limited is measured differently than its book value, which is the value of Amdocs that is recorded on the company's balance sheet. Investors also form their own opinion of Amdocs' value that differs from its market value or its book value, called intrinsic value, which is Amdocs' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Amdocs' market value can be influenced by many factors that don't directly affect Amdocs' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Amdocs' value and its price as these two are different measures arrived at by different means. Investors typically determine Amdocs value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Amdocs' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.